Buchang Pharma Subsidiary Signs Two Technology Development Contracts for Class III Medical Devices

Corporate Action
โดย CLS·Read original
Summary · why it matters

Baoding Tianhao, a wholly owned subsidiary of Buchang Pharma, has signed two technology development entrustment contracts with Beijing Xinliyan, commissioning the latter to carry out the research and development, registration application, and entrusted manufacturing of injectable silk fibroin filler and injectable hydroxyapatite filler. Both products are national Class III medical devices, intended respectively for the treatment of midface volume loss and mandibular contour deficiency. All ownership, intellectual property rights, and revenue rights of the collaborative products belong exclusively to Baoding Tianhao. The transaction amount is exempt from disclosure due to commercial confidentiality.

Impact on stocks 1

Others▲ · 1 stocks

Off-coverage companies 2

Baoding Tianhao Biotechnology Co., Ltd.Private▲ Positive
Technologyrelevance

As the subsidiary, it directly commissions R&D for two new injectable fillers, gaining IP and revenue rights.

Beijing XinliyanPrivate▲ Positive
Demandrelevance

Receives technology development contracts, generating revenue from R&D services and future manufacturing.

© 2026 MarketDXNews